Monashee Investment Management LLC Invests $1.83 Million in Kyverna Therapeutics, Inc. $KYTX

Monashee Investment Management LLC bought a new position in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 195,000 shares of the company’s stock, valued at approximately $1,833,000.

Several other institutional investors also recently modified their holdings of the stock. Empowered Funds LLC acquired a new position in shares of Kyverna Therapeutics during the 4th quarter worth about $169,000. Propel Bio Management LLC acquired a new position in shares of Kyverna Therapeutics during the 4th quarter worth about $6,267,000. TD Asset Management Inc grew its position in shares of Kyverna Therapeutics by 35.2% during the 4th quarter. TD Asset Management Inc now owns 222,796 shares of the company’s stock worth $2,094,000 after buying an additional 58,000 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Kyverna Therapeutics by 209.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 133,530 shares of the company’s stock worth $1,255,000 after buying an additional 90,398 shares during the period. Finally, Simplify Asset Management Inc. acquired a new position in shares of Kyverna Therapeutics during the 4th quarter worth about $1,808,000. 18.08% of the stock is currently owned by institutional investors and hedge funds.

Kyverna Therapeutics Trading Up 2.7%

NASDAQ:KYTX opened at $7.87 on Friday. Kyverna Therapeutics, Inc. has a fifty-two week low of $2.52 and a fifty-two week high of $13.67. The company has a debt-to-equity ratio of 0.13, a current ratio of 8.15 and a quick ratio of 8.15. The stock has a market capitalization of $478.42 million, a PE ratio of -2.40 and a beta of 1.95. The business’s 50-day simple moving average is $9.00 and its 200-day simple moving average is $8.55.

Kyverna Therapeutics (NASDAQ:KYTX) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.09. Sell-side analysts expect that Kyverna Therapeutics, Inc. will post -2.78 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on KYTX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Friday, March 27th. JPMorgan Chase & Co. decreased their target price on Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research report on Wednesday, May 13th. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of Kyverna Therapeutics in a research report on Wednesday, June 3rd. Finally, Wall Street Zen lowered Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.00.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.